MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
The Lancet Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

832 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
832 works in the cohort · of 4,299,418page 3 of 17

Labels cover 9 of 832 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 832 of 832 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
The expanding role of primary care in cancer control
Greg Rubin, Annette J. Berendsen, S. M. Crawford, Rachel Dommett, Craig C. Earle, Jon Emery +30 more
2015· review· en· The Lancet Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
544
citations
affno abstractunlabeled
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga, Seock‐Ah Im, Hiroji Iwata, Javier Cortés, Zefei Jiang, Carlos L. Arteaga +18 more
2017· article· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
539
citations
affno abstractunlabeled
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park +192 more
2020· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
498
citations
affno abstractunlabeled
Hereditary diffuse gastric cancer: updated clinical practice guidelines
Vanessa Blair, Maybelle McLeod, Fátima Carneiro, Daniel G. Coit, Johanna L D'Addario, Jolanda M. van Dieren +59 more
2020· review· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
480
citations
affno abstractunlabeled
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan‐Khan, Paula Cramer, Fatih Demırkan, Graeme Fraser, Rodrigo Santucci Silva, Sebastian Grosicki +23 more
2015· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
410
citations
← previousnext →

How this was built: Screen · Findings · About